Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Bon voyage!

    A Baylor team discovers how to culture norovirus, solving a 40-year-old problem

    Four decades after discovery of the norovirus, researchers have found a way to culture it in vitro that could boost chances of a vaccine.

    Published on 9/15/2016
  • Figure: Differential effect

    KOR-recting MS Targets & Mechanisms Differential effect Regrowing myelin sheaths that are lost from axons in patients with multiple sclerosis involves the proliferation of oligodendrocyte precursor cells (OPCs) in …

    Published on 9/15/2016
  • Table: BioCentury Product Profile

    KOR-recting MS Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A compound that activates kappa opioid receptor (KOR)-mediated differentiation of …

    Published on 9/15/2016
  • Table: Myelin modulators

    KOR-recting MS Targets & Mechanisms Myelin modulators Potential new remyelination modulators in multiple sclerosis. At least 15 targets are reported in the literature to regulate the development of oligodendrocytes…

    Published on 9/15/2016
  • Table: Pipeline in repair

    KOR-recting MS Targets & Mechanisms Pipeline in repair With myelin repair gaining momentum as a strategy to treat multiple sclerosis, at least 12 compounds or programs from 11 companies and 2 institutions, are now …

    Published on 9/15/2016
  • KOR-recting MS

    Why the MS field might invest in biased opioid agonists

    Two reports of successful myelin repair using kappa opioid agonists in models of MS add a known but tricky receptor to a growing list of remyelination targets.

    Published on 9/15/2016
  • Box: Bad guy's good side

    Biased against pain Targets & Mechanisms Bad guy's good side While the β-arrestin ARRB2 has been viewed as the bad actor in the side effects of opioid drugs, a Duke University Medical Center team has discovered the…

    Published on 9/1/2016
  • Figure: Breaking form

    Biased against pain Targets & Mechanisms Breaking form Creating safer opioid analgesics may require breaking away from the standard morphinan scaffold (red) found in classical opioids such as morphine, which bind …

    Published on 9/1/2016
  • Table: BioCentury Product Profile

    Biased against pain Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Biased agonist at the mu opioid receptor, MOR (PZM21 or derivative) Concept MOR binding …

    Published on 9/1/2016
  • Biased against pain

    How Epiodyne aims to make opioids safer

    Pushing the limits of computational drug discovery, an academic team finds a new type of molecule that separates good from bad signaling at opioid receptors.

    Published on 9/1/2016
  • Figure: Cleanup crew

    Forty Seven and counting Targets & Mechanisms Cleanup crew In a pair of Nature and Science Translational Medicine studies, Stanford University teams have shown blocking the "don't eat me" cell surface protein CD47 …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: Chasing CD47

    Forty Seven and counting Targets & Mechanisms Chasing CD47 At least six companies are developing compounds to block the anti-phagocytic cell surface protein CD47, either with CD47-targeting antibodies or with …

    Published on 8/25/2016
  • Forty Seven and counting

    Stanford and Forty Seven Inc. count up new indications for CD47 blockade

    With CD47 gaining status as the go-to target in oncology, a pair of Stanford studies suggest the target could extend to cardiovascular disease, transplant biology and more.

    Published on 8/25/2016
  • Box: A cut too far

    Niche for the aged Targets & Mechanisms A cut too far For effective wound repair, muscle stem cells - known as satellite cells - must spring into action and then return to quiescence. A study published last month …

    Published on 8/11/2016
  • Figure: Healing young again

    Niche for the aged Targets & Mechanisms Healing young again A pair of Nature Medicine studies have identified a receptor, integrin β1, and one of its ligands, fibronectin, which could be targeted to boost muscle …

    Published on 8/11/2016
  • Niche for the aged

    Targeting integrin β1 or fibronectin for muscle repair in the aged

    A pair of studies identified integrin β1 and fibronectin as two sides of the same coin for improving post-injury muscle regeneration in the elderly.

    Published on 8/11/2016
  • Cereblon ambition

    A structural motif could help Celgene find new targets to send to the proteasome

    Celgene has identified a structural motif at the heart of thalidomide's MOA, and is looking for more proteins with the feature that could pave a path to new drugs.

    Published on 8/4/2016
  • Figure: Good riddance to new rubbish

    Cereblon ambition Targets & Mechanisms Good riddance to new rubbish Celgene Corp. (NASDAQ:CELG) hopes to extend the degradation-based mechanism of action of thalidomide and its analogs, known as imids, to new …

    Published on 8/4/2016
  • Table: BioCentury Product Profile

    Cereblon ambition Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A platform to find substrates for degradation induced by thalidomide analogs (imids) Concept…

    Published on 8/4/2016
  • Figure: Maverick microglia

    Effectorless efficacy Targets & Mechanisms Maverick microglia Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AC Immune S.A. have shown that using standard mAbs to treat CNS diseases may …

    Published on 7/28/2016
  • Table: BioCentury Product Profile

    Effectorless efficacy Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product An anti-tau mAb incapable of binding microglia Concept Reduce tau pathology without …

    Published on 7/28/2016
  • Effectorless efficacy

    How Genentech is making mAbs safer for CNS diseases

    By designing therapeutic mAbs to fly under the radar of brain microglial cells, Genentech is making the modality safer for treating CNS diseases without sacrificing efficacy.

    Published on 7/28/2016
  • Figure: Crossing paths

    Making sense of sensors Targets & Mechanisms Crossing paths Since TLR9 was first identified as an innate immune receptor that detects microbial DNA and helps initiate a response to infection two decades ago, new …

    Published on 7/28/2016
  • Figure: Some like it hot

    Making sense of sensors Targets & Mechanisms Some like it hot Activation of nucleic acid sensors such as TLR9 can make so-called "cold" immunosuppressed tumors into "hot" ones that become infiltrated with antitumor…

    Published on 7/28/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993